EXPAND
DEAD

Serial Number

97844690

Owner

ILIAS Biologics Inc.

Attorney

Janice Housey

Filing Date

Mar 17, 2023

Add to watchlist:

No watchlists yet
View on USPTO

EXPAND Trademark

Serial Number: 97844690

EXPAND is a trademark filed by ILIAS Biologics Inc. on March 17, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

ILIAS Biologics Inc. (11 trademarks)

40-20 Techno 6-ro, Yuseong-gu
Daejeon 34014 , KR

Entity Type: 03

Trademark Details

Filing Date

March 17, 2023

Registration Date

Not Registered

Goods & Services

Biological preparations for medical or veterinary purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; biochemical preparations for medical or veterinary purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceuticals featuring drug delivery system, namely, pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; preparations for intracellular drug delivery, namely, drug delivery agents in the form of capsules, tablets, pills, powders, liquids, suspensions, injection, creams, emulsions, gels, liniments, lotions, ointments, patches, solutions, syrups, aerosols, granules, implants, inhalants, pellets that facilitate the delivery of pharmaceutical preparations; pharmaceuticals for the treatment of immune system disease; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of cellular diseases; chemico-pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; protein preparations, namely, protein supplements; biotechnological preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; reagents for medical use; pharmaceuticals for human purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; biochemical pharmaceuticals for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease; biological tissue cultures for medical purposes; diagnostic reagents for medical use; pharmaceuticals for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease, allergies, skin diseases, endocrine diseases, gastrointestinal diseases, hematologic diseases, diseases and disorders of the immune system, ophthalmic diseases, kidney diseases, urinary disease

Biological preparations, other than for medical or veterinary purposes; biological preparation for use in experiments other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; biological preparations for use in experiments containing exosomes carrying the desired protein, other than for medical or veterinary use; biochemical preparations for gene recombination for scientific or laboratory purposes; biological tissue cultures, other than for medical or veterinary purposes; cells for scientific or laboratory purposes; biological preparations for scientific or laboratory purposes other than for medical or veterinary use; diagnostic reagents for scientific or research use; diagnostic reagents for use in biological or genetic engineering for scientific or research use and medical laboratory use; reagents for scientific or medical research use; biological preparations for use in biotechnology industry and science, other than for medical purpose; cell growth media for growing cells for use in scientific research; biochemicals for in vitro and in vivo scientific use; reagents for medical research; biological preparation containing exosomes for use in manufacture of cosmetics; protein for use in the manufacture of cosmetics; chemical preparations for use in the manufacture of cosmetics; chemical additives for use in the manufacture of cosmetics; proteins for the food industry

Drug discovery services using cells; research on the subject of pharmaceuticals; development of pharmaceutical preparations; biomedical research services; scientific research relating to biology; industrial research in the fields of biology; scientific research consultation and providing scientific information in the fields of biology; scientific research consultation and providing scientific information in the fields of biology; laboratory research in the field of biology; biological research and analysis; biological research services; product development of devices for biological chemicals analysis; product development in the field of biologics; research of biologics, namely, scientific study and research in the field of biologics; research and development of technology for biotechnology; consultancy in the field of biotechnology; biotechnology research; providing scientific research information relating to scientific analysis of the genetic information via online networks; biological information check, namely, genetic testing for scientific research purposes

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Apr 30, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 30, 2024 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 10, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 10, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 10, 2024 CNRT
ASSIGNED TO EXAMINER
Dec 13, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 10, 2023 NWOS
NEW APPLICATION ENTERED
Mar 21, 2023 NWAP